1Hymecromone: A Clinical Prescription Hyaluronan Inhibitor for Efficiently2Blocking COVID-19 Progression

3

4 Shuai Yang*, Yun Ling*, Fang Zhao*, Wei Li, Zhigang Song, Lu Wang, Qiuting Li, Mengxing Liu,

5 Ying Tong, Lu Chen, Daoping Ru, Tongsheng Zhang, Kaicheng Zhou, Baolong Zhang, Peng Xu,

6 Zhicong Yang, Wenxuan Li, Yuanlin Song, Jianqing Xu, Tongyu Zhu, Fei Shan[†], Wenqiang Yu[†],
7 Hongzhou Lu[†].

- Hongzno
- 8

9 Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences & Shanghai Public Health

10 Clinical Center & Department of General Surgery, Huashan Hospital, Cancer Metastasis

11 Institute Shanghai Medical College, Fudan University, Shanghai, China (S Yang, W Li, Q Li, M

12 Liu, Y Tong, L Chen, D Ru, T Zhang, K Zhou, B Zhang, P Xu, Z Yang, W Li); Shanghai Public

13 Health Clinical Center, Fudan University, Shanghai, China (Y Ling, F Zhao, Z Song, J Xu);

14 **Zhongshan Hospital, Fudan University, Shanghai, China** (L Wang, Y Song, T Zhu).

- 15 *Contributed equally as first authors
- 16 [†]Contributed equally
- 17
- 18 Correspondence to:

19 Dr. Fei Shan, Department of radiology, Shanghai Public Health Clinical Center, Fudan University,

20 Shanghai 201599, China; Prof. Wenqiang Yu, Laboratory of RNA Epigenetics, Institutes of Biomedical

21 Sciences & Shanghai Public Health Clinical Center & Department of General Surgery, Huashan

22 Hospital, Cancer Metastasis Institute, Shanghai Medical College, Fudan University, Shanghai 200030,

23 China; Dr. Hongzhou Lu, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201599,

24 & The Third People's Hospital of Shenzhen, Shenzhen 518112, China.

25 shanfei@shphc.org.cn; wenqiangyu@fudan.edu.cn; luhongzhou@shphc.org.cn

27 Summary

Background We previously found that human identical sequences (HIS) of SARS-CoV-2 promote the
 clinical progression of COVID-19 by upregulating hyaluronan (HA). As one of the drugs for
 hyaluronan inhibition, hymecromone was chosen for evaluating its therapeutic effects on COVID-19.

31

32 Methods ELISA was performed to detect the level of HA in COVID-19 patients. We first analyzed the 33 correlation between the level of plasma HA and clinical parameters (lymphocytes, C-reactive protein, 34 D-dimer, and fibrinogen). We then assessed the correlation between the plasma HA level and 35 pulmonary lesions, which were quantified by using artificial intelligence based on chest CT scans, 36 including ground-glass opacity (GGO) and consolidation. Furthermore, we assessed the effect of 37 hyaluronan treatment on the formation of pulmonary lesions in mice and evaluated the role of 38 hymecromone on hyaluronan production in cultured cells. Finally, 94 of the 144 confirmed 39 COVID-19 patients received oral hymecromone in addition to standard care, whereas the others with 40 only standard care were treated as control. Abnormal serological markers in two groups were selected 41 to determine the efficacy of hymecromone.

42

43 **Findings** Plasma HA was closely relevant to clinical parameters, including lymphocytes (n = 158; r =44 -0.50; P < 0.0001), CRP (n = 156; r = 0.55; P < 0.0001), D-dimer (n = 154; r = 0.38; P < 0.0001), and 45 fibrinogen (n = 152; r = 0.37; P < 0.0001), as well as the mass (n = 120; r = 0.30; P = 0.0008) and 46 volume (n = 120; r = 0.30; P = 0.0009) of GGO, the mass (n = 120; r = 0.34; P = 0.0002) and volume 47 (n = 120; r = 0.35; P < 0.0001) of consolidation. Mice experiment further verified that hyaluronan 48 could cause pulmonary lesions directly. Hymecromone remarkably reduced HA via downregulating 49 HAS2/HAS3 expression. Accordingly, the number of lymphocytes recovered more quickly as the fold 50 change of lymphocytes per day was higher in hymecromone-treated patients (n = 8) than the control 51 group (n = 5) (P < 0.01). Moreover, 89% patients with hymecromone treatment had pulmonary lesion 52 absorption while only 42% patients in control group had pulmonary lesion absorption (P < 0.0001). 53 54 Interpretation Hyaluronan is closely correlated with COVID-19 progression and can serve as a

Interpretation Hyaluronan is closely correlated with COVID-19 progression and can serve as a
 plasma biomarker. As a promising treatment for COVID-19, hymecromone deserves our further
 efforts to determine its effect in a larger cohort of COVID-19 patients.

57

Funding National Key R&D Program of China, Major Special Projects of Basic Research of Shanghai
Science and Technology Commission, and Shanghai Science and Technology Innovation Action Plan,
Medical Innovation Research Special Project, Research of early identification and warning of acute
respiratory infectious diseases.

63 Research in context

64 Evidence before this study

65 Our previous study revealed that human identical sequences (HIS) of SARS-CoV-2 promotes 66 hyaluronan production in COVID-19 patients. We searched PubMed for studies associated with 67 hyaluronan and COVID-19 using the search terms ("hyaluronan" OR "hyaluronic acid" OR 68 "hymecromone") AND ("COVID-19" OR "SARS-CoV-2") without any language restrictions from 69 inception up to May 27, 2021. The studies showed that hyaluronan was present in lung alveoli of 70 severe COVID-19 and SARS-CoV-2 infection-induced hyaluronan. Meanwhile, one report showed that 71 hyaluronan was related to the severity of COVID-19 based on the research of 32 COVID-19 cases. As 72 the inhibitor of hyaluronan synthesis, hymecromone is already an approved drug for patients with 73 biliary spasms in Europe and Asia. However, it is unclear whether hymecromone is an effective 74 therapeutic drug for COVID-19.

75

76 Added value of this study

We found significant correlations between hyaluronan and clinical parameters (lymphocytes,
C-reaction protein, D-dimer, fibrinogen, and pulmonary lesions) in COVID-19 patients. Hyaluronan is
the essential material for the induction of ground-glass opacity formation in the lung of COVID-19
patients. The lymphopenia of COVID-19 may be due to T cell exhaustion caused by hyaluronan.
Notably, we demonstrated that hymecromone could accelerate the recovery of lymphopenia and
pulmonary lesion absorption of COVID-19 in clinical sets.

83

84 Implications of all the available evidence

85 Our finding shows that hymecromone could significantly improve the clinical manifestations,

- 86 especially in severe COVID-19 patients. Reducing hyaluronan using specific drugs could be a
- 87 promising and alternative therapeutic strategy for COVID-19, especially for the treatment of patients
- 88 with lymphopenia and pulmonary lesion.

90 Introduction

91 As of September 17th 2021, more than 226 million infections of COVID-19 have been 92 confirmed worldwide, resulting in approximately 4,666,334 deaths according to the WHO 93 Coronavirus Disease (COVID-19) Dashboard. Significantly, the emergence of B.1.617.2 (Delta) 94 variant has caused breakthrough infections and exacerbated this epidemic¹, which highlights the 95 importance of exploring the common strategy for the treatment of COVID-19 caused by diverse 96 SARS-CoV-2 variants. With such a rapid variation and high mortality of SARS-CoV-2, there is an 97 urgent need for appropriate treatment to prevent the deterioration of moderate and severe COVID-19, 98 and to reduce the mortality.

99 Recently, we identified five identical sequences between the genomes of SARS-CoV-2 and human, 100 termed human identical sequences (HIS), which can promote the accumulation of hyaluronan by 101 activating hyaluronic acid synthase 2 (HAS2)². Accordingly, adult respiratory distress syndrome 102 (ARDS) is one of the typical clinical symptoms in severe COVID-19 patients³, and hyaluronan 103 (hyaluronic acid, HA) is accumulated in the lung of patients with ARDS⁴. Of note, hyaluronan is higher 104 in lung tissue of deceased COVID-19 patients than that in healthy people⁵. Hyaluronan regulates 105 diverse biological and pathological processes involved in inflammation responses, immune responses, 106 and tissue injury⁶. Meanwhile, the other common features of severe COVID-19 patients include 107 inflammatory cytokine storm, lymphocytopenia, and ground-glass opacity (GGO) in the lung^{7,8}. 108 However, the alteration of hyaluronan and its potential role is still unclear.

109 Here, we found hyaluronan was markedly increased in patients with pulmonary lesions and that 110 there is a significant correlation between plasma level of hyaluronan and other clinical parameters in 111 COVID-19 patients, including lymphocytes, C-reactive protein, D-dimer, and fibrinogen. Moreover, 112 we observed that hyaluronan was significantly relevant to pulmonary lesions, including GGO and the 113 consolidation of lung in COVID-19 patients, which further confirmed that hyaluronan directly induced 114 GGO and the consolidation of lung in mice. Notably, we aimed to use the inhibitor of HA synthesis, 115 hymecromone, an approved prescription drug used for treating biliary spasm in Europe and Asia⁹, to 116 evaluate its therapeutic effect for COVID-19.

117

118 Materials and Methods

119 Patient enrollment and experiment animal

120 All COVID-19 patients enrolled in this study have received a written informed consent upon admission 121 into the Shanghai Public Health Clinical Center (SPHCC), the designated hospital for COVID-19 patients in Shanghai, China¹⁰. This study was approved by the Ethics Committee of the SPHCC 122 123 (YJ-2020-S123-02). COVID-19 for patients was confirmed based on the Guidelines of the Diagnosis 124 and Treatment of New Coronavirus Pneumonia (version 7) published by the National Health 125 Commission of China. Exclusion criteria for COVID-19 patients were listed as below: 1) Serious 126 non-infectious pulmonary diseases, including pulmonary tumor, pulmonary edema, atelectasis, 127 pulmonary embolism, pulmonary eosinophilic infiltration, pulmonary vasculitis etc.; 2) Severe liver 128 and kidney dysfunction: a) ALT and AST value were more than 10 times higher than the upper limit of 129 normal value; b) serum creatinine value was more than 1.5 times higher than the upper limit of normal 130 value; c) total bilirubin was more than 2 times the upper limit of normal value; 3) Patients with biliary 131 obstruction; 4) Pregnant women (urine or serum pregnancy test positive) or lactating women; 5) Other 132 factors considered unsuitable by the researchers for this trial, or the situation that may increase the risk 133 of subjects or interfere with the clinical trial.

Adult C57BL/6 mice were purchased from Shanghai Jiesijie experimental animal Co., Ltd (Shanghai, China). All mice were 6–8 weeks of age. Handling of animals was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the SPHCC Ethics Committee.

138

139 Procedures

140 Laboratory parameters, chest computed tomographic (CT) scans, treatment and outcome data were 141 collected according to the patients' medical records. The mild and severe cases of COVID-19 were 142 distinguished by pulmonary lesions based on chest CT. The mild COVID-19 patients did not have 143 pulmonary lesions, while the severe COVID-19 patients had pulmonary lesions including GGO and/or 144 consolidation. We first detected the plasma hyaluronan levels of COVID-19 patients (n=158) in 145 SPHCC using Enzyme-linked Immunol sorbent assay (ELISA) as described previously². Meanwhile, 146 twenty health subjects were recruited to evaluate their plasma hyaluronan levels as the control group. 147 The 48.43 ng/ml of hyaluronan was sensitive to distinguish COVID-19 patients and health subjects via 148 receiver operating characteristic curve (ROC) analysis. Then, we divided the COVID-19 patients into 149 two groups (HA \geq 48.43 ng/ml; HA < 48.43 ng/ml) and confirmed whether there are significant 150 differences between hyaluronan and other clinical parameters (lymphocytes, C-reactive protein, 151 D-dimer, and fibrinogen). The lesion regions in the lungs of COVID-19 patients were quantified by artificial intelligence (AI) as previous description^{11,12}. Furthermore, we analyzed the correlation 152 153 between hyaluronan and these clinical parameters.

Adult male mice were used to assess the impact of hyaluronan on the lung lesions, such as GGO and consolidation. The 200 to 400 kDa of hyaluronan dissolved in 1×PBS was intratracheal to mice (60 mg/kg), while the 1×PBS treatment was as the control group. Then, the formation of lung lesions in two groups were monitored via QuantumGX microCT on day four.

158 Moreover, we evaluated whether hymecromone can reduce hyaluronan levels in the cell using 159 HEK293T and HUVEC cells. Twenty-four hours after HEK293T and HUVEC were treated with 160 DMSO or hymecromone (250 µg/ml), cell culture mediums were collected to detect the hyaluronan 161 levels using the Hyaluronan DuoSet ELISA (R&D Systems) according to the manufacturer's 162 descriptions. Meanwhile, we extracted the total RNA of HEK293T and HUVEC cells treated with 163 DMSO or hymecromone. As previously described in our study², quantitative RT-PCR (RT-qPCR) was 164 performed to evaluate whether hymecromone can decrease the expression of HAS1, HAS2, and HAS3 (HAS1/2/3), which are the known hyaluronic acid syntheses. The expression of GAPDH served as the 165 normalized endogenous control. Relative mRNA expression was calculated via the $2^{-\Delta\Delta Ct}$ method (The 166 167 primers are shown in Supplementary Table 1).

Finally, 144 COVID-19 patients were recruited to assess whether hymecromone could improve the clinical parameters of COVID-19. Among these patients, 94 patients were oral hymecromone administration (2 tablets, 0.2 g/tablet, three times a day, before meals) combined with conventional treatment as the experimental group. The other 50 patients only underwent conventional treatment as the control group. Administration of hymecromone continued until the patients recovered from COVID-19. Chest CT scans, lymphocyte counts, C-reactive protein (CRP), D-dimer, fibrinogen, and plasma hyaluronan were critical clinical indicators during COVID-19 patient treatment.

175

176 Outcomes

177 Outcomes of COVID-19 patients were assessed based on the clinical indicators and chest CT images.

178 The primary outcomes were the changes in lymphocyte counts, CRP, fibrinogen, and D-dimer in 179 patients. The secondary outcome was the change in the patients' chest CT results. We also monitored

180 the suspected serious adverse reactions in accordance with regulatory requirements.

181

182 Statistical analysis

183 The COVID-19 patients with pulmonary lesions were defined as severe while the others were 184 considered mild. Twenty health subjects without any clinical symptoms were defined as the normal 185 group. Samples (n=158) were collected to compare the levels of hyaluronan in these three groups using 186 the Mann-Whitney test. ROC analysis was used to identify the hyaluronan concentration for 187 distinguishing normal groups and COVID-19 patients. Based on this analysis, COVID-19 patients were 188 divided into two groups (HA \ge 48.43 ng/ml; HA < 48.43 ng/ml). The significant differences between 189 typical clinical indicators (such as lymphocytes, C-reactive protein, D-dimer, and fibrinogen) in these 190 two groups were calculated by the Mann-Whitney test. Two-tailed Spearman's correlation analysis was 191 performed to evaluate the correlation between hyaluronan and these clinical indicators. Unpaired T test 192 was used to confirm the significant differences between hyaluronan and HAS1/2/3 expression among 193 hymecromone-treated cells and DMSO-treated cells.

194 In addition, 144 COVID-19 patients were recruited to assess the effect of hymecromone for 195 COVID-19. We further analyzed the effect of hymecromone using these patients with abnormal clinical 196 parameters, including lymphocytes, C-reactive protein, D-dimer, and fibrinogen. For the primary 197 outcomes, we calculated the fold changes of these clinical parameters per day in the 198 hymecromone-treated group and control group and compared the clinical significances using the 199 Mann-Whitney test. For the secondary outcome of change in chest CT results, we compared the 200 hymecromone-treatment group and the control group, including the patients with GGO. According to 201 CT quantitative analysis, we evaluated the change of pulmonary lesions, including improvement and 202 exacerbation in COVID-19 patients classified by different hospitalization days (X < 14 day; 14 day \leq X 203 < 28 day; 28 day $\leq X < 35$ day; X represents the hospitalization days). We calculated the percentage of 204 improvement and exacerbation in different groups and analyzed the significance between the 205 hymecromone-treated group and the control group using Fisher's exact tests. The P value less than 0.05 206 was statistically significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.001; ns, not 207 significant).

208

209 Role of the funding source

210 The funders of this study had no role in study design, data collection, data analysis, data interpretation,

211 or writing of the report. The corresponding authors had full access to all the data in the study and had

- 212 final decision-making power to submit for publication.
- 213

214 Results

215 Hyaluronan is a considerable biomarker to predict COVID-19 progression

216 A total of 158 COVID-19 patients in SPHCC were conducted to investigate the potential relationship 217 between hyaluronan and the typical clinical indicators for COVID-19. Specifically, 18% (28 of 158) 218 patients without pulmonary lesions were mild, while the other patients (130 of 158) with pulmonary 219 lesions including GGO and consolidation were severe. The plasma HA level showed no significant 220 difference between healthy subjects and mild COVID-19 patients, while the plasma HA level in severe 221 COVID-19 patients were significantly higher than that in the other two groups (figure 1A), indicating 222 there is a potential relation between hyaluronan and pulmonary lesions. Further ROC analysis 223 identified that the 48.43 ng/ml of hyaluronan was sensitive for distinguishing COVID-19 patients and 224 healthy subjects (figure 1B). Then, 158 COVID-19 patients were divided into low HA group (HA <225 48.43 ng/ml) and high HA group (HA \ge 48.43 ng/ml).

226 Lymphopenia is one of the typical clinical symptoms in severe COVID-19 patients¹³. It is reported that hyaluronan can result in the death of the activated T cell¹⁴. Here, we found that lymphocytes 227 228 were markedly decreased in the high HA group of COVID-19 patients (figure 1C). As shown in figure 229 1D, hydronan was negatively correlated with lymphocytes (n = 158; r = -0.50; P < 0.0001). The 230 subsets of T lymphocytes, CD4+ T cells, CD8+ T cells, and CD45+ T cells were also significantly 231 reduced in COVID-19 patients with high HA (supplemental figure 1A-C). Similarly, hyaluronan was 232 negatively correlated with the CD4+ T cells (n = 151; r = -0.44; P < 0.0001), CD8+ T cells (n = 151; r233 = -0.53; P < 0.0001), and CD45+ T cells (n = 151; r = -0.49; P < 0.0001) (supplemental figures 1D-F).

Inflammation is another common clinical symptom involved in COVID-19 patients, usually assessed via CRP. Noteworthily, low molecular weight of hyaluronan is an important inflammation mediator.⁶ Surprisingly, we found that CRP markedly increased in the high HA group (figure 2A) and was positively correlated with hyaluronan (n = 156; r = 0.55; P < 0.0001) (figure 2B). Recent studies revealed abnormal blood coagulation in COVID-19 patients⁷. Clinically, D-dimer and fibrinogen are commonly used to assess a patient's blood coagulation. We found that both were higher in COVID-19 patients with high HA and were positively correlated with hyaluronan (figures 2C-F).

Collectively, these results reveal that the increase of hyaluronan is significantly relevant to the
reduction of lymphocytes and the upregulation of CRP, D-dimer, and fibrinogen in COVID-19 patients,
suggesting hyaluronan may play a key role during the clinical progression of COVID-19.

244

245 Hyaluronan is fundamental for ground-glass opacity formation in the lung of COVID-19 patients

246 It is well-known that ground-glass opacity of lungs is the other typical clinical manifestation of COVID-19 patients¹⁵, which can develop into consolidation. We quantified the mass and volume of the 247 248 lung lesion regions involved in GGO and consolidation in 120 COVID-19 patients using 249 uAI-Discover-NCP (beta version). In general, GGO was defined in a range from -750 HU to -300 HU, and the consolidation region was defined from -300 HU to 50 HU¹⁶. Notably, hyaluronan was 250 251 positively correlated with the mass (n = 120; r = 0.30; P = 0.0008) and volume (n = 120; r = 0.30; P = 0.0008) 252 0.0009) of GGO, which was also the case in consolidation (supplemental figure 2). A typical case for 253 this correlation is shown in figure 3. The plasma HA levels, GGO, and consolidation clearly increased 254 on the fourth day, compared to the first day (figures 3A-C), indicating the mass and volume of 255 pulmonary lesions (GGO and consolidation) increased along with the upregulation of hyaluronan. CT 256 images further showed the exacerbation of pulmonary lesions, including GGO and consolidation in this 257 patient on the fourth day instead of the first day (figure 3D). Recent research found that there is

jelly-like liquid in the lung of COVID-19 patients³. Given that hyaluronan can absorb water reaching
1000 times its molecular weight¹⁷, we hypothesize that hyaluronan may be one of the determinants for
GGO of lung in COVID-19 patients.

To confirm our hypothesis, we delivered hyaluronan intratracheally to the lung in male mice. Significantly, CT images showed that GGO and consolidation of lung occurred in mice treated with hyaluronan while there were no pulmonary lesions in mice treated with $1 \times PBS$ (figure 4). Therefore, these findings supported that hyaluronan acts as a critical material for the formation of GGO and consolidation of the lung in COVID-19 patients, indicating that inhibition of HA synthesis may be a promising strategy for relieving pulmonary lesions in COVID-19 patients.

267

268 Hymecromone significantly decreases hyaluronan bydownregulating HAS2/HA3

269 Based on these findings, we realized that reduction of HA production could be an alternative 270 therapeutic strategy for COVID-19, especially for patients with pulmonary lesions. As a derivative of 271 coumarin, 4-MU was shown to inhibit the production of HA^{18} . Fortunately, we noticed there is a 272 commercial drug, 4-MU, also called hymecromone, which is an approved prescription drugs in China, 273 USA and Europe, even acting as over the counter drugs in some areas. We first verified the inhibitory 274 effect of hymecromone on HA production in HEK293T and HUVEC cells. As expected, HA from 275 culture medium in HEK293T and HUVEC cells treated with hymecromone (250 µg/ml) were 276 significantly lower than that in DMSO-treated cells (figure 5A). There are three known hyaluronic acid 277 synthases, including HAS1, HAS2, and HAS3 (HAS1/2/3). As shown in figures 5B-C, hymecromone 278 treatment remarkably downregulated the expression of HAS2/HAS3, but did not affect the expression of 279 HASI in HEK293T and HUVEC cells (figures 5B-C). Therefore, hymecromone inhibits the production 280 of hyaluronan by decreasing HAS2/HA3 expression.

281

282 Hymecromone accelerates the recovery of clinical manifestations in COVID-19 patients

283 To further assess whether hymecromone is efficient inimproving the clinical parameters of 284 COVID-19, we recruited 144 confirmed COVID-19 patients. Among these patients, 94 (65%) patients 285 with hymecromone treatment were in the clinical trial group, while 50 (35%) patients with support 286 treatment were in the control group (figure 6A). Given the significant correlation between hyaluronan 287 and clinical indicators, we set changes in lymphocytes, CRP, fibrinogen, and D-dimer as the primary 288 endpoints, and the change in chest CT results as the secondary endpoint. To objectively evaluate the 289 effect of hymecromone on COVID-19, we selected COVID-19 patients with abnormal clinical 290 indicators in these two groups. Specifically, there were 5 patients with decreased lymphocytes, 4 291 patients with increased CRP, 7 patients with increased fibrinogen, and 8 patients with increased 292 D-dimer in the control group. In the clinical trial group, there were 8 patients with decreased 293 lymphocytes, 5 patients with increased CRP, 7 patients with increased fibrinogen, and 6 patients with 294 increased D-dimer (figure 6B).

Firstly, we focused on the change of pulmonary lesions in COVID-19 patients during hymecromone treatment. We determined the situation of pulmonary lesions, including GGO and consolidation based on CT quantitative analysis. Surprisingly, all the patients with hospitalization days < 14 day had improved pulmonary lesions after hymecromone treatment (figure 7A). The percentage of pulmonary lesion improvement in patients with hymecromone treatment were significantly higher than that in control group (P = 0.0002). For the patients with hospitalization between 28 to 35 days, the percentage of pulmonary lesion improvement rate was 86% (6 of 7) patients in the trial group, and 45%

302 (2 of 9) in the control group, respectively. In total, 89% (41 of 46) patients with hymecromone 303 treatment had pulmonary lesion absorption, while only 42% (42 of 100) in the control group had 304 pulmonary lesion absorption (P < 0.0001). Different regions of pulmonary lesions in typical cases in 305 two groups were gradually absorbed (figure 7B). As such, patients have better improvement of 306 pulmonary lesions after hymecromone treatment. Thus, hymecromone could promote the pulmonary 307 lesion absorption of COVID-19.

308 Then, we calculated and compared the fold changes of these various clinical indicators per day in 309 these two groups with lymphopenia, CRP elevation, fibrinogen elevation, and D-dimer elevation, 310 respectively. As shown in figure 8A, the fold change of lymphocytes per day was remarkably higher in 311 hymecromone-treated patients, compared to the control group. Similarly, the fold changes of CRP or 312 fibrinogen in hymecromone-treated patients were higher than that in the control group (supplemental 313 figures 3-5). These results implied that hymecromone contributes to the improvement of clinical 314 parameters of COVID-19. Moreover, the fold change of D-dimer tended to be improved, but it is not 315 significant between control group and clinical trial group, which may be due to to the limited number 316 of patients.

317 These findings demonstrated that hymecromone is a promising drug for effectively improving the

318 clinical manifestations of COVID-19.

320 Discussion

Our previous study has found that human identical sequences (HIS) of SARS-CoV-2 could promote hyaluronan upregulation by NamiRNA-Enhancer network during the progression of COVID-19², indicating that reduction in hyaluronan may be an alternative therapeutic strategy for COVID-19, which is supported by the other reports found that hyaluronan was increased in severe COVID-19 patients^{5,19,20}. As an inhibitor of HA synthesis, hymecromone is an approved drug for biliary spasms treatment. Here, we aimed to assess whether hymecromone could promote the prognosis of COVID-19.

327 Hyaluronan is an excellent biomarker to predict COVID-19 progression. We found that 328 hyaluronan was significantly elevated in severe COVID-19 patients. Consistent with our results, 329 increases in hyaluronan was also confirmed in severe or critical patients with $COVID-19^{20}$. Notably, 330 hyaluronan is accumulated in the bronchoalveolar lavage fluid (BALF) and serum samples of patients 331 with ARDS²¹, a relatively serious COVID-19. We also found that hyaluronan was significantly correlated with lymphocytes, CRP, D-dimer, and fibrinogen. These clinical indicators are proven 332 biomarkers for the clinical progression of COVID-19²². All these findings demonstrated that 333 334 hyaluronan was relevant to COVID-19 progression. Additionally, we showed that hyaluronan positively correlates with quantified chest CT results, a recently identified parameter to predict the 335 336 severity of COVID-19¹¹. This result further supported that hyaluronan can serve as a better biomarker 337 for predicting the clinical progression of COVID-19.

338 Most importantly, our results provide vital insights into the typical clinical symptoms occurring in 339 COVID-19. As we all know, GGO is one of typical CT manifestations of COVID-19 patients²³. 340 However, the pathophysiologic mechanism of GGO is still unclear. We showed that hyaluronan can 341 cause GGO and consolidation of lung in mice, providing direct evidence that hyaluronan is 342 fundamental for GGO formation. Consistent with our results, transcriptome sequencing of cells in 343 BALF from COVID-19 patients revealed differentially altered genes enriched in the hyaluronan metabolic pathway¹⁹. The appearance of GGO were further interpreted by the facts that the water 344 345 absorption of hyaluronan can reach 1000 times its molecular weight¹⁷, possibly resulting in the formation of jelly-like liquid in the lung of COVID-19 patients³. In addition to GGO, lymphopenia is 346 347 another typical clinical symptom in severe COVID-19 patients¹³. We found that the crucial subsets of T 348 lymphocytes, CD4+ T cells, CD8+ T cells, and CD45+ T cells were also significantly decreased in 349 COVID-19 patients with high HA. Meanwhile, the negative correlation between hyaluronan and 350 diverse T cell subsets confirmed that hyaluronan was associated with the reduction of T lymphocytes. In line with this sight, hyaluronan can induce the activated T cell death by binding to its ligand CD44¹⁴. 351 352 Notably, CD4+ T lymphocytes become rapidly activated after SARS-CoV-2 infection²⁴, which provides the condition needed for the binding of HA to CD44 located in activated T cells, leading to their death. 353 354 In other words, T cell exhaustion mediated by hyaluronan may potentially underly lymphopenia of 355 COVID-19 patients.

356 Hymecromone could accelerate the recovery of clinical manifestations in COVID-19 patients. At present, the therapeutic strategy for COVID-19 is mainly symptomatic supportive treatment in clinic²⁵. 357 358 Here, we found that hymecromone inhibited hyaluronan production by suppressing the expression of 359 HAS1/2. Additionally, hymecromone significantly improved lymphopenia of COVID-19 patients, 360 indicating that declines in hyaluronan via hymecromone administration promote the recovery of 361 lymphopenia. Likewise, hymecromone decreased the CRP and fibrinogen elevation of COVID-19 362 patients. Also remarkably, hymecromone accelerated pulmonary lesions absorption. It has already been 363 reported that dexamethasone and metformin can significantly decrease the mortality of patients with

severe COVID-19²⁶⁻²⁸. Accordingly, these results may be explained by the reports that dexamethasone
and metformin can also rapidly decline hyaluronan synthesis by downregulating *HAS2* expression^{29,30},
which may contribute the therapeutic effects of these two drugs on COVID-19. In addition, we found
most HIS is quite conservative by analyzing 159258 genomes of SARS-CoV-2 (unpublished data),
suggesting hyaluronan caused by HIS may be an important therapeutic target for diverse SARS-CoV-2
variants. All these evidences support that hymecromone could be a potential and effective drug for
COVID-19 patients even infected with delta variant.

There are several limitations in our study. First, the total number of patients involved in our clinical trial is relatively insufficient, which requires a larger sample and multi-center clinical study in the future. Second, we did not evaluate whether hymecromone can reduce the mortality rates of COVID-19 patients because of no critical patients in this clinical trial. Third, given that the exact value of hyaluronan may be different using diverse methods, it is necessary to identify the hyaluronan concentration to clinically distinguish the healthy subjects and COVID-19 patients by uniform standard methods.

Overall, the increased hyaluronan is significantly correlated with the decreased lymphocytes and pulmonary lesions of COVID-19 patients. Hymecromone administration can markedly improve the clinical manifestations of COVID-19 patients. Thus, hymecromone could be a potential and efficient drug for COVID-19 therapy, which is needed to further clarify the effect of hymecromone on COVID-19 in a larger sample of clinical trials. Our findings highlight that inhibiting the synthesis of hyaluronan with specific drugs is a promising therapeutic strategy for COVID-19.

385 Contributors

F.S., W.Y., and H.L. conceived and designed this study. S.Y., Y.L., F.Z., L.W., Z.S., M.L., Y.T., L. C.,
B.Z., Y.S. and F.S. did the follow-up investigation. S.Y., Y.L., F.Z., L.W., Q.L., D.R., T.Z., K.Z., P.X.,
and Z.Y. collected the data. S.Y., W.L., Q.L., and W.L. did the statistical analysis. S.Y. and F.Z. drafted
the initial manuscript and all the authors revised the manuscript critically. H.L. and W.Y. had full access
to the all data and took responsibility for the integrity and accuracy of the data in the study.

391

392 Declaration of interests

Wenqiang Yu et al are listed as inventors on patents' application related to this study. There are no otherrelationships or activities that could influence this submitted work.

395

396 Data sharing

In this study, the personal data of patients are sensitive and can't be shared in public. However, requestsfor data could be made to the Shanghai Public Health Clinical Center.

399

400 Acknowledgments

401 This work was supported by the National Key R&D Program of China (2018YFC1005004), Major 402 Special Projects of Basic Research of Shanghai Science and Technology Commission (18JC1411101), 403 Shanghai Science and Technology Innovation Action Plan, Medical Innovation Research Special 404 Project (20Z11900900). We thank Yue Yu for her editorial help and comments on the manuscript. We 405 thank Ying Guo and Cuiyun Zhu for their help on patient data collection. We thank all the participants 406 involved in this study. We also appreciate the assistance and support of Shanghai Public Health Clinical 407 Center.

409	References
410	1. Baj A, Novazzi F, Pasciuta R, et al. Breakthrough Infections of E484K-Harboring SARS-CoV-2
411	Delta Variant, Lombardy, Italy. Emerg Infect Dis 2021; 27(12).
412	2. Li W, Yang S, Xu P, et al. Human Identical Sequences of SARS-CoV-2 Promote Clinical
413	Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network. BioRxiv
414	2020: 2020.11.04.361576.
415	3. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory
416	distress syndrome. The Lancet Respiratory Medicine 2020; 8(4): 420-2.
417	4. Hällgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic acid)
418	in the lung in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139(3): 682-7.
419	5. Hellman U, Karlsson MG, Engstrom-Laurent A, et al. Presence of hyaluronan in lung alveoli in
420	severe Covid-19: An opening for new treatment options? J Biol Chem 2020; 295(45): 15418-22.
421	6. Liang J, Jiang D, Noble PW. Hyaluronan as a therapeutic target in human diseases. Adv Drug
422	<i>Deliv Rev</i> 2016; 97 : 186-203.
423	7. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N
424	Engl J Med 2020; 382 (18): 1708-20.
425	8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
426	in Wuhan, China. Lancet 2020; 395(10223): 497-506.
427	9. Nagy N, Kuipers HF, Frymoyer AR, et al. 4-methylumbelliferone treatment and hyaluronan
428	inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol 2015; 6:
429	123.
430	10. Li Q, Wang L, Wang B, Lu H. The COVID-19-designated hospitals in China: preparing for public
431	health emergencies. Emerg Microbes Infect 2021; 10(1): 998-1001.
432	11. Shi W, Peng X, Liu T, et al. A deep learning-based quantitative computed tomography model for
433	predicting the severity of COVID-19: a retrospective study of 196 patients. Ann Transl Med 2021; 9(3):
434	216.
435	12. Shan F, Gao Y, Wang J, et al. Abnormal lung quantification in chest CT images of COVID-19
436	patients with deep learning and its application to severity prediction. <i>Med Phys</i> 2021; 48 (4): 1633-45.
437	13. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and
438	Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020;
439	323 (20): 2052-9.
440	14. Ruffell B, Johnson P. Hyaluronan induces cell death in activated T cells through CD44. <i>J Immunol</i>
441	2008; 181 (10): 7044-54.
442	15. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical
443	Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J
444	Roentgenol 2020; 214 (5): 1072-7.
445	16. Jacobs C, van Rikxoort EM, Twellmann T, et al. Automatic detection of subsolid pulmonary
446	nodules in thoracic computed tomography images. <i>Med Image Anal</i> 2014; 18 (2): 374-84.
447	17. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. <i>Cell</i>
448	<i>Death Differ</i> 2020; 27 (5): 1451-4.
449	18. Kultti A, Pasonen-Seppanen S, Jauhiainen M, et al. 4-Methylumbelliferone inhibits hyaluronan
450	synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2
451	and 3. <i>Exp Cell Res</i> 2009; 315 (11): 1914-23.
452	19. Andonegui-Elguera S, Taniguchi-Ponciano K, Gonzalez-Bonilla CR, et al. Molecular Alterations

453 Prompted by SARS-CoV-2 Infection: Induction of Hyaluronan, Glycosaminoglycan and 454 Mucopolysaccharide Metabolism. Arch Med Res 2020.

- 455 20. Ding M, Zhang Q, Li Q, Wu T, Huang YZ. Correlation analysis of the severity and clinical 456 prognosis of 32 cases of patients with COVID-19. Respir Med 2020; 167: 105981.
- 457 21. Esposito AJ, Bhatraju PK, Stapleton RD, Wurfel MM, Mikacenic C. Hyaluronic acid is associated 458
- with organ dysfunction in acute respiratory distress syndrome. Crit Care 2017; 21(1): 304.
- 459 22. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 460 disease progression. Crit Rev Clin Lab Sci 2020; 57(6): 389-99.
- 461 23. Yang S, Shi Y, Lu H, et al. Clinical and CT features of early stage patients with COVID-19: a
- 462 retrospective analysis of imported cases in Shanghai, China. Eur Respir J 2020; 55(4).
- 463 24. Zhang W, Li L, Liu J, et al. The characteristics and predictive role of lymphocyte subsets in
- 464 COVID-19 patients. Int J Infect Dis 2020; 99: 92-9.
- 465 25. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission,
- 466 Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020.
- 467 26. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 -
- 468 Preliminary Report. N Engl J Med 2020.
- 469 27. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and
- 470 Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and
- 471 COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324(13): 1307-16.
- 472 28. Luo P, Qiu L, Liu Y, et al. Metformin Treatment Was Associated with Decreased Mortality in
- 473 COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg 2020; 103(1): 474 69-72.
- 475 29. Gebhardt C, Averbeck M, Diedenhofen N, et al. Dermal hyaluronan is rapidly reduced by topical
- 476 treatment with glucocorticoids. J Invest Dermatol 2010; 130(1): 141-9.
- 477 30. Sainio A, Takabe P, Oikari S, et al. Metformin decreases hyaluronan synthesis by vascular smooth
- 478 muscle cells. J Investig Med 2020; 68(2): 383-91.
- 479
- 480

481 Figure Legends

482

483 Figure 1: The increase of hyaluronan is accompanied with the severity in COVID-19 patients

484 (A) The plasma hyaluronan level of COVID-19 patients and normal health subjects were evaluated by 485 ELISA. The classification of mild and severe of COVID-19 was based on ground-glass opacity (GGO) 486 of chest CT. (B) ROC of the plasma hyaluronan level in normal volunteers and COVID-19 patients. 487 The 48.43 ng/ml of hyaluronan is sensitivity value to distinguish the normal subjects and COVID-19 488 patients. (D) Counts of lymphocytes upon admission plotted against hyaluronic acid. Two-tailed 489 Spearman's correlation analysis was performed to evaluate the correlation between hyaluronan and 490 lymphocyte counts. The significant difference in (A) and (C) was analyzed by the Mann–Whitney test. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.001; ****, *P* < 0.0001; ns, not significant. 491

492

493 Figure 2: The plasma level of hyaluronan as a typical indicator of COVID-19 patients in clinic

494 C-reactive protein (A), D-dimer (C), and fibrinogen (E) of COVID-19 patients were showing based on 495 the 48.43 ng/ml of hyaluronan. Data was presented by Mean \pm SD. The significant difference was 496 confirmed by the Mann–Whitney test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; is, 497 not significant. The relation of C-reactive protein (B), D-dimer (D), and fibrinogen (F) against 498 hyaluronic acid were determined by two-tailed Spearman's correlation analysis.

499

500 Figure 3: The size of pulmonary lesions and the level of hyaluronan in one typical case

(A) The plasma HA levels of this case were detected at the first day and fourth day. (B-C) The mass (B) and volume (C) of pulmonary lesions including GGO and consolidation were calculated via the automatic lung segmentation technology of AI based on CT images of this case at the first day and fourth day. (D) Represented CT images showing the pulmonary lesions in this case. The original CT results were shown in black-and-white images while the marked lesion regions of CT results were shown in color images. Red regions indicated GGO, and green regions indicated consolidation.

507

508 Figure 4: Hyaluronan directly induces GGO and consolidation in adult mice

Represented CT images of lungs in mice with different treatment were shown. Adult C57BL/6 mice
were used to assess whether hyaluronic acid induces pulmonary lesions. We directly delivered
hyaluronan (200~400 kDa) to the trachea (n = 3), and 1×PBS treatment was as the control group (n =
3). Then, we monitored the lungs of mice in two groups via QuantumGX microCT at the fourth day.

514 Figure 5: Hymecromone decreases hyaluronan by downregulating hyaluronic acid synthases

515 (A) ELISA detected the hyaluronic acid of culture medium in HEK293T and HUVEC treated with 516 DMSO or hymecromone (250 µg/ml). The fold change of hyaluronic acid was normalized to DMSO. 517 (B-C) RT-qPCR evaluated the mRNA levels of *HAS1*, *HAS2*, and *HAS3* in HEK293T (B) and 518 HEK293T treated with DMSO or hymecromone (250 µg/ml). Data was presented by Mean \pm SD. The 519 significant difference was confirmed by unpaired t test. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.001; ****, 520 *P* < 0.0001; ns, not significant.

521

522 Figure 6: The Consort Diagram and Statistical Table of recruited COVID-19 patients for this 523 clinical trial

524 (A) The Consort Diagram for the clinical trial contains 144 COVID-19 patients. Among these patients,

525 94 patients were in the trial group while the rest were in the control group. Changes in lymphocytes,

526 CRP, fibrinogen, and D-dimer were set as the primary endpoints and change in chest CT results were

527 set as the secondary endpoint. (B) Statistical Table of COVID-19 patients with change in clinical

- 528 indicators of control group and experimental group within 35 days.
- 529

Figure 7: Hymecromone can effectively alleviate the pulmonary lesions of severe COVID-19patients

(A) Comparison of change in chest CT results between control group and hymecromone treatment
group. Fisher's exact tests were used to evaluate the significance between control group and
experiment group. (B) Represented CT images of COVID-19 patients with support or hymecromone
treatment. The original CT results were shown in black-and-white images of two groups while the
marked lesion regions of CT results were shown in color images of two groups. Red regions indicated
GGO, and green regions indicated consolidation.

538

539 Figure 8: Hymecromone accelerate the recovery of COVID-19 patients from lymphocytopenia

540 Changes in lymphocytes (A), CRP (B), fibrinogen (C), and D-dimer (D) were calculated as the fold

- 541 change of diverse clinical indicators per day in patients with lymphocytopenia. Data was presented by
- 542 Mean \pm SD. The significant difference was confirmed by the Mann–Whitney test. *, P < 0.05; **, P < 0.05;
- 543 0.01; ***, *P* < 0.001; ****, *P* < 0.0001; ns, not significant.
- 544

545 **Supplementary materials** 546 547 Supplementary Figure 1: Correlation between hyaluronan and subtype of lymphocytes cell 548 counts in COVID-19 patients 549 (A-C) The scatter plots showing CD4+ cell counts (A), CD8+ cell counts (B), and CD45+ cell counts 550 (C) of COVID-19 patients classified by the 48.43 ng/ml of hyaluronan. Data was expressed by Mean \pm 551 SD. The significant difference was confirmed by Mann–Whitney test. *, P < 0.05; **, P < 0.01; ***, P 552 < 0.001; ****, P < 0.0001; ns, not significant. (D-F) Counts of CD4+ cells (D), CD8+ cells (E), and 553 CD45+ cells (F) upon admission plotted against hyaluronic acid, calculated by two-tailed Spearman's 554 correlation analysis. 555 556 Supplementary Figure 2: hyaluronan and pulmonary lesions in severe COVID-19 patients 557 (A-B) Scatter plot showing relation on the mass (A) and volume (B) of GGO against hyaluronic acid. 558

(C-D) Scatter plot showing relation on the mass (C) and volume (D) of the consolidation region against hyaluronic acid. Mass and volume of pulmonary lesions were calculated via the automatic lung segmentation technology of AI based on CT images of severe COVID-19 patients. GGO was defined a range from -750 HU to -300 HU, and the consolidation region was defined from -300 HU to 50 HU. Two-tailed Spearman's correlation analysis was performed to identify the relation of pulmonary lesions against hyaluronic acid.

564

565 Supplementary Figure 3: hymecromone helps to decrease the CRP in COVID-19 patients

566 Changes in lymphocytes (A), CRP (B), fibrinogen (C), and D-dimer (D) were calculated as the fold 567 change of diverse clinical indicators per day in patients with CRP elevation. Data was presented by 568 Mean \pm SD. The significant difference was confirmed by the Mann–Whitney test. *, P < 0.05; **, P <569 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

570

571 Supplementary Figure 4: hymecromone helps to decrease fibrinogen in COVID-19 patients

572 Changes in lymphocytes (A), CRP (B), fibrinogen (C), and D-dimer (D) were calculated as the fold 573 change of diverse clinical indicators per day in patients with fibrinogen elevation. Data was presented 574 by Mean \pm SD. The significant difference was confirmed by the Mann–Whitney test. *, P < 0.05; **, P575 < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.


576

577 Supplementary Figure 5: The effect of hymecromone on the elevation of D-dimer in COVID-19 578 patients


579 Changes in lymphocytes (A), CRP (B), fibrinogen (C), and D-dimer (D) were calculated as the fold 580 change of diverse clinical indicators per day in patients with D-dimer elevation. Data was presented by 581 Mean \pm SD. The significant difference was confirmed by the Mann–Whitney test. *, P < 0.05; **, P <582 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

583


584 Supplementary Table 1: The primer sequences for RT-qPCR.































Figure 6



В

Groups	Lymphopenia	CRP elevation	Fibrinogen elevation	D-dimer elevation
Control	5	4	7	8
Hymecromone	8	5	7	6

А

Γ


medRxiv preprint doi: https://doi.org/10.1101/2021.10.19.21263786; this version posted October 19, 2021. The copyright holder for this preprint (who has granted medRxiv points in preprint in perpetuity.) is the author/funder, who has granted medRxiv points in perpetuity.

olucomoutori	It is made available under a CC			BV NC ND 40 International license			
Treatment	Improvement	Exacerbation		Improvement	Exacerbation	P	
Control, n(%)	10 (42)	14 (58)	Yes	30 (45)	37 (55)	0.0002	
Hymecromone, n(%)	11 (100)	0 (0)	Tes	24 (86)	4 (14)	0.0002	
Classification	28 day \leq X $<$ 35 day			Total			
Treatment	Improvement	Exacerbation	Р	Improvement	Exacerbation	Р	
Control, n(%)	2 (22)	7 (78)	0.0406	42 (42)	58 (58)	<0.0001	
Hymecromone, n(%)	6 (86)	1 (14)	0.0400	41 (89)	5 (11)	<0.0001	

В

Control

Hymecromone






Figure 8